Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;36(7):624-39.
doi: 10.1177/0333102415610874. Epub 2015 Oct 26.

The Influence of Genetic Constitution on Migraine Drug Responses

Affiliations

The Influence of Genetic Constitution on Migraine Drug Responses

Anne Francke Christensen et al. Cephalalgia. .

Abstract

Objective: Specific acute treatments of migraine are 5HT1B/D receptor agonists; triptans and ergotamine, but only two-thirds of patients respond well without side effects. No migraine-prophylactic drugs are specific to migraine. Prophylactic drugs are selected by time-consuming "trial and error." Personalized treatment is therefore much needed. The objective of this study was to test the effect of 12 single nucleotide polymorphisms (SNPs) significantly associated with migraine on migraine drug responses.

Methods: Semi-structured migraine interviews including questions on drug responses, blood samples and genotyping were performed on 1806 unrelated migraine cases recruited from the Danish Headache Center. Association analyses were carried out using logistic regression, assuming an additive model for the genetic effect. The effect on drug responses was tested for a combined genetic score and for each of the 12 SNPs. Significant findings were subsequently tested in an independent replication sample of 392 unrelated Danish migraine cases.

Results: A single risk variant, rs2651899 in PRDM16, was significantly associated with efficacy of triptans with an odds ratio (OR) of treatment success of 1.3, and a higher combined genetic score was significantly associated with efficacy of triptans with an OR of success of up to 2.6. A number of SNPs showed nominal preferential association with the efficacy of triptans and others with prophylactic drugs. Analyses of triptans and ergotamine complemented each other and gave a stronger signal when analyzed together. The associations between response to triptans and genetic load and rs2651899 were partially confirmed in the independent sample.

Conclusion: We show for the first time an association between genetic constitution and migraine drug response. This is a first step toward future individualized medicine.

Keywords: Migraine; drug response; migraine genetics; migraine treatment; triptans.

Similar articles

See all similar articles

Cited by 10 articles

  • Headaches and polygenic scores.
    Vilhjálmsson BJ, Privé F. Vilhjálmsson BJ, et al. Neurol Genet. 2019 Oct 24;5(6):e368. doi: 10.1212/NXG.0000000000000368. eCollection 2019 Dec. Neurol Genet. 2019. PMID: 31872052 Free PMC article. No abstract available.
  • Migraine polygenic risk score associates with efficacy of migraine-specific drugs.
    Kogelman LJA, Esserlind AL, Francke Christensen A, Awasthi S, Ripke S, Ingason A, Davidsson OB, Erikstrup C, Hjalgrim H, Ullum H, Olesen J, Folkmann Hansen T; DBDS Genomic Consortium, The International Headache Genetics Consortium. Kogelman LJA, et al. Neurol Genet. 2019 Oct 24;5(6):e364. doi: 10.1212/NXG.0000000000000364. eCollection 2019 Dec. Neurol Genet. 2019. PMID: 31872049 Free PMC article.
  • Advances in genetics of migraine.
    Sutherland HG, Albury CL, Griffiths LR. Sutherland HG, et al. J Headache Pain. 2019 Jun 21;20(1):72. doi: 10.1186/s10194-019-1017-9. J Headache Pain. 2019. PMID: 31226929 Free PMC article. Review.
  • Optimising migraine treatment: from drug-drug interactions to personalized medicine.
    Pomes LM, Guglielmetti M, Bertamino E, Simmaco M, Borro M, Martelletti P. Pomes LM, et al. J Headache Pain. 2019 May 17;20(1):56. doi: 10.1186/s10194-019-1010-3. J Headache Pain. 2019. PMID: 31101004 Free PMC article. Review.
  • The Role of Genetic Polymorphisms in Chronic Pain Patients.
    Knezevic NN, Tverdohleb T, Knezevic I, Candido KD. Knezevic NN, et al. Int J Mol Sci. 2018 Jun 8;19(6):1707. doi: 10.3390/ijms19061707. Int J Mol Sci. 2018. PMID: 29890676 Free PMC article. Review.
See all "Cited by" articles

LinkOut - more resources

Feedback